Thomas Deal
Stock Analyst at Raymond James
(1.62)
# 3,481
Out of 5,070 analysts
4
Total ratings
33.3%
Success rate
0.7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Thomas Deal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KYMR Kymera Therapeutics | Initiated Coverage: Buy | $140 | $113.46 | +23.39% | 1 | Oct 8, 2026 | |
| NKTR Nektar Therapeutics | Initiated Coverage: Hold | n/a | $39.22 | - | 1 | Oct 8, 2026 | |
| ODTX Odyssey Therapeutics | Initiated Coverage: Buy | $42 | $18.99 | +121.17% | 1 | Oct 8, 2026 | |
| PALI Palisade Bio | Initiated Coverage: Buy | $6 | $1.43 | +319.58% | 1 | Oct 8, 2026 |
Kymera Therapeutics
Oct 8, 2026
Initiated Coverage: Buy
Price Target: $140
Current: $113.46
Upside: +23.39%
Nektar Therapeutics
Oct 8, 2026
Initiated Coverage: Hold
Price Target: n/a
Current: $39.22
Upside: -
Odyssey Therapeutics
Oct 8, 2026
Initiated Coverage: Buy
Price Target: $42
Current: $18.99
Upside: +121.17%
Palisade Bio
Oct 8, 2026
Initiated Coverage: Buy
Price Target: $6
Current: $1.43
Upside: +319.58%